Luspatercept
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 326 publications
Luspatercept and thrombotic events in patients with myelodysplastic syndrome: a target trial emulation framework using TriNetX database.
Journal: Leukemia & lymphoma
Published: June 10, 2026
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.
Journal: Hemoglobin
Published: June 09, 2026
Erythroferrone in β-thalassemia: Systematic review and meta-analysis.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: May 23, 2026
Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors.
Journal: Expert opinion on pharmacotherapy
Published: May 08, 2026
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting.
Journal: Journal of hematology & oncology
Published: April 19, 2026
A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Journal: Leukemia & lymphoma
Published: March 30, 2026
Luspatercept in Transfusion-Dependent Thalassemia With Red Blood Cell Antibodies: A Case Series.
Journal: EJHaem
Published: March 12, 2026
Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia.
Journal: Haematologica
Published: March 10, 2026
Case Report: life-threatening haemothorax due to extramedullary haematopoiesis in a patient with Beta-thalassaemia major.
Journal: Frontiers in medicine
Published: February 07, 2026
Luspatercept ameliorates disease phenotype and complications in the Townes mouse model of sickle cell disease.
Journal: The Journal of clinical investigation
Published: February 02, 2026
Last Updated: 06/30/2026